Cellonis' Cell Treatment for Glioma May Prevent Tumor Recurrence and Improve Quality of Life Significantly

BEIJING, Nov. 3, 2010 /PRNewswire-Asia/ -- "For brain cancer patients after surgery, the combined DC-CIK and stem cell therapy from Cellonis Biotechnologies can be a very effective method in preventing cancer recurrence," says renowned cancer doctor Dr. Dinggang Li. "This is a new hope for cancer patients".

The unique therapy combines the latest stem cell and immuno technology with the benefits of Traditional Chinese Medicine. Inger Marie Olsen from Norway has recently concluded a cycle of the treatment in Beijing, and she has been in a stable condition since the first cycle in September 2009.

Dr. Li has been guiding the treatment of Inger. "Inger's general condition has improved very much," he remarks. "She can now speak, move, eat and sleep much better, she has improved a great deal. I think her quality of life is almost back to normal."

"I was diagnosed with cancer in 2005," Inger explains in a recent interview. "I had chemotherapy, radiotherapy and three surgeries, but the cancer still came back. A friend of mine read about this new therapy on the internet and the people of my town arranged a fund to help me come here."

The Cellonis cancer therapy combines the latest research into cancer stem cells with the advantages of Traditional Chinese Medicine to create a unique cancer treatment. Dendritic cells, cultured and processed from blood taken from the patient's body, are loaded with glioma stem cell antigens to create a vaccine that can activate the immune system to kill cancer cells as well as the cancer stem cells responsible for tumor initiation and recurrence. Another patient like Inger with glioma who undertook the treatment earlier this year, Mr. Guy Spavold from Canada, has been in stable condition since April with a good quality of life.

"In my clinical experience patients with an advanced stage of brain tumor after surgery should be given this therapy to prevent cancer recurrence," continues Dr. Li. "For glioma patients this comprehensive therapy can be a real benefit and improve their life quality significantly."

Cellonis Biotechnologies focuses on R&D and the clinical application of personalized stem cell therapies and immunotherapies for patients with diseases including cancer, diabetes and central nervous system disorders.

CONTACT:

Urs. J. Lienert

COO-International

Cellonis

+86-150-1054-7487

Email: ipsc@cellonis.com , urs.lienert@cellonis.com

Web: www.cellonis.com , www.cellonis-anticancer.com (coming soon)

 

 

SOURCE Cellonis Biotechnologies Co., Ltd.

CONTACT: Urs. J. Lienert, COO-International, Cellonis, +86-150-1054-7487


Web Site: http://www.cellonis-anticancer.com

 

Posted: November 2010

View comments

Hide
(web3)